Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SMITHKLINE BEECHAM'S TAGAMET I.V. UPPER GI BLEEDING INDICATION

Executive Summary

SMITHKLINE BEECHAM'S TAGAMET I.V. UPPER GI BLEEDING INDICATION approved by FDA, the company announced Dec. 9. FDA cleared the supplemental NDA on Nov. 13, but SmithKline Beecham waited to make the announcement until the American Society of Hospital Pharmacists meeting in New Orleans. The approved label now indicates Tagamet (cimetidine) continuous infusion for "prevention of upper gastrointestinal bleeding in critically ill patients." Tagamet is the first H[2] antagonist to carry the indication. "For reasons that are not completely clear, critically ill hospitalized patients are at high risk of developing upper gastrointestinal tract damage as a complication of severe illness or traumatic injury," SmithKline Beecham said. "Studies have shown that nearly 90% of cardiac surgery patients and up to 100% of severe injury patients may suffer some damage to the lining of the upper GI tract. In up to 30% of patients, this damage causes clinically significant bleeding that may be fatal," the company stated. The condition is also found in "critically ill patients suffering from shock, infection, burns, and central nervous system injury." The new indication is the second for Tagamet this year. The oral dosage form of the drug was approved March 7 for gastroesophageal reflux disease (GERD)("The Pink Sheet" May 6, In Brief). Tagamet's U.S. patent expires in May 1994. SmithKline Beecham filed for the new indication on April 10, 1990. FDA's Gastrointestinal Drugs Advisory Committee recommended approval of the new indication on July 25 ("The Pink Sheet" July 29, p. 4). The new Tagamet label includes data from the company's TA-SO2 study, which the advisory committee found convincing. That 131- patient trial showed a 14% incidence of bleeding in Tagamet patients versus 33% in placebo patients. The approved dose for the new indication is 50 mg/hr continuous infusion. Patients with low creatinine levels should use half the recommended dose, the label says. "Treatment beyond seven days has not been studied." One issue of concern for the advisory committee was a possible increase in mortality for patients in the study on Tagamet. The committee voted that there was an increased risk with cimetidine, but agreed that the risk did not preclude approval of the drug. SmithKline Beecham's press release announcing the approval notes that "bleeding associated with mortality was observed in one of the nine patients receiving Tagamet, compared to four of 22 placebo-treated patients."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel